|1.||Giugliani, Roberto: 6 articles (06/2014 - 08/2006)|
|2.||Muenzer, Joseph: 5 articles (01/2012 - 08/2006)|
|3.||Beck, Michael: 5 articles (01/2012 - 08/2006)|
|4.||Whiteman, David A H: 4 articles (01/2015 - 02/2011)|
|5.||Harmatz, Paul: 4 articles (05/2013 - 08/2006)|
|6.||Vellodi, Ashok: 4 articles (06/2011 - 08/2006)|
|7.||Sohn, Young Bae: 3 articles (02/2015 - 01/2013)|
|8.||Jin, Dong-Kyu: 3 articles (02/2015 - 01/2013)|
|9.||Scarpa, Maurizio: 3 articles (01/2014 - 12/2010)|
|10.||Gucsavas-Calikoglu, Muge: 3 articles (02/2011 - 08/2006)|
|1.||Mucopolysaccharidosis II (Hunter Syndrome)
02/19/2007 - "A recent randomised, double-blind, placebo-controlled, multi-centre and multinational study in phase II/III conducted with 96 patients with Hunter syndrome over one year showed that the administration of 0.5 mg/kg doses of idursulfase significantly improved the final 'combined' score, which was the sum of the changes in the percentage of predicted forced vital capacity and in the 6-minute walk test, in comparison to the response obtained with a placebo. "
02/01/2015 - "This study indicates that the safety and efficacy of idursulfase beta are similar to those reported in Hunter syndrome patients aged 6 years or older."
02/01/2015 - "The objective of this study was to evaluate the safety and efficacy of ERT with idursulfase beta in Hunter syndrome children younger than 6 years. "
08/01/2006 - "To evaluate the safety and efficacy of recombinant human iduronate-2-sulfatase (idursulfase) in the treatment of mucopolysaccharidosis II. Ninety-six mucopolysaccharidosis II patients between 5 and 31 years of age were enrolled in a double-blind, placebo-controlled trial. "
05/01/2013 - "In conclusion, the data showed an improvement in growth rate in patients with Hunter syndrome following idursulfase treatment."
01/01/2014 - "The effect of recombinant human iduronate-2-sulfatase (Idursulfase) on growth in young patients with mucopolysaccharidosis type II."
11/01/2013 - "[Efficacy and safety of idursulfase therapy in patients with mucopolysaccharidosis type II with and without comparison to placebo: systematic review and meta-analysis]."
01/01/2012 - "We present a 3-year follow-up of a boy with mucopolysaccharidosis type II (MPS II) who had idursulfase therapy initiated at the age of 3 months and compare his clinical course to his healthy twin brother. "
06/01/2011 - "To evaluate the occurrence of infusion-related reactions (IRRs) in patients with mucopolysaccharidosis type II (MPS II) receiving idursulfase enrolled in the observational database HOS - the Hunter Outcome Survey. "
10/01/2010 - "To use our experience with patients in the observational database HOS - the Hunter Outcome Survey - to evaluate the feasibility of home infusions of idursulfase for patients with mucopolysaccharidosis type II (MPS II). "
|3.||Cystic Fibrosis (Mucoviscidosis)
01/01/2014 - "Enzyme replacement therapy with intravenous infusions of idursulfase has emerged as a new treatment for mucopolysaccharidosis type II. To evaluate the effectiveness and safety of enzyme replacement therapy with idursulfase compared to other interventions, placebo or no intervention, for treating mucopolysaccharidosis type II. We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group's Trials Register (date of last search 22 July 2013).We also searched EMBASE, PubMed and the Literature Latino-Americana e do Caribe em Ciências da Saúde (LILACS) (date of last search 09 July 2013). "
01/01/2011 - "Enzyme replacement therapy with intravenous infusions of idursulfase has emerged as a new treatment for mucopolysaccharidosis type II. To evaluate the effectiveness and safety of enzyme replacement therapy with idursulfase compared to other interventions, placebo or no intervention, for treating mucopolysaccharidosis type II. We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group's Trials Register (date of last search 01 September 2011).We also searched EMBASE, PubMed and the Literature Latino-Americana e do Caribe em Ciências da Saúde (LILACS) (date of last search October 2009). "
03/01/2013 - "While enzyme replacement therapy (ERT) with idursulfase has been shown to improve many somatic features of the disease, some such as dysostosis multiplex and cardiac valve disease appear irreversible once established, and little is known about the preventative effects of ERT in pre-symptomatic patients. "
|5.||Anaphylaxis (Anaphylactic Shock)
06/01/2013 - "SPT with idursulfase demonstrated positive results in all patients with anaphylaxis. "
06/01/2013 - "Three patients (8.8%) showed anaphylaxis by infusion of idursulfase. "
06/01/2013 - "The purpose was to evaluate the occurrence of infusion-related allergic reactions, including anaphylaxis, to idursulfase in patients with MPS II receiving ERT and to elucidate its possible mechanism. "
06/01/2013 - "SPT is useful in predicting the occurrence of anti-idursulfase IgE-mediated anaphylaxis during infusion."
06/01/2013 - "Anaphylaxis related to infusion of idursulfase is mediated by anti-idursulfase IgE antibody, which might be produced by de novo synthesis. "
|6.||Immunoglobulin E (IgE)
|7.||human GAA protein (Myozyme)
|1.||Enzyme Replacement Therapy